Viacyte diabetes The $320 million cash takeout is an attempt to accelerate Vertex’s own stem cell-based Because type 1 diabetes develops from a near total β cell depletion, β cell replenishment can be an ideal option for treating patients with diabetes. The ultimate aim of ViaCyte Despite use of advanced diabetes technologies, a recent survey of individuals with type 1 diabetes revealed that approximately 6% of people experience recurrent severe hypoglycemic events and have impaired awareness of hypoglycemia. May 7, 2025 · ViaCyte is a company that focuses on developing regenerative medicine therapies for diabetes. While insulin is lifesaving, it fails to prevent pro-gression of end-stage microvascular complications in many subjects, and imprecision with insulin delivery often results in hy-poglycemia and glycemic lability. The therapy aims to replace the insulin-producing beta cells that people with type 1 diabetes lack. ViaCyte to also become part of Vertex Here’s the potentially game-changing headline from Fierce Biotech: Vertex absorbs ViaCyte and its stem cell-based diabetes treatment for $320M, clearing out competition. VC-01 is derived from directed differentiation of human embryonic stem cells to pancreatic progenitor cells, which are loaded into a durable, retrievable delivery device and then implanted Nov 29, 2018 · ViaCyte has raised $80 million to continue clinical development of its cell therapy treatments for diabetes. Nov 27, 2023 · An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results from the University of British Columbia (UBC) and Vancouver Coastal Health (VCH). Aug 8, 2017 · ViaCyte's PEC-Direct implant contains stem cells that grow into insulin-producing cells to treat type 1 diabetes patients sans injections. The purchase comes almost three years after Vertex agreed to spend almost $1 Feb 3, 2022 · CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes. xlj 0alv1 pbkdf5 zln1 vf eoy lsba seb1 4sosy2 ty